Highlights
- Postoperative initiation of GLP-1 receptor agonists (GLP-1RAs) after curative-intent liver resection for hepatocellular carcinoma (HCC) in patients with type 2 diabetes (T2D) reduces tumor recurrence risk and improves overall survival compared to dipeptidyl peptidase-4 inhibitors (DPP-4is).
- The largest target trial emulation to date involved 1249 patients from 36 hospitals in China, leveraging real-world electronic medical records for prolonged follow-up (median 50.8 months).
- GLP-1RAs may exert anti-tumor effects beyond glycemic control, suggesting actionable biological mechanisms influencing HCC progression and recurrence.
- Results from the observational emulation warrant prospective clinical trials to establish causality and guide clinical decision-making.
Background
Specialty calculators
For clinical reference; use professional judgment.
